CATUG and Crystal Bio Establish Strategic Partnership, Launching "CATUG-Crystal" Joint Lab Dedicated to Advanced Nucleic Acid Analytical Services

February 23, 2024 12:00 AM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

CAMBRIDGE, Mass. and CRANBURY, N.J., Feb. 22, 2024 /PRNewswire/ -- CATUG Inc. (CATUG) and Crystal Bio, a member of Crystal Pharmatech, announced today a long-term strategic partnership to provide advanced nucleic acid-based drug analytical services. CATUG, a distinguished global entity specializing in integrated nucleic acid and drug delivery CRDMO services, is combining capabilities with Crystal Bio, a premier provider of analytical services for biologics in CMC, preclinical development, and clinical stages. The two specialized organizations will provide clients with comprehensive nucleic acid services and analytical solutions in the North American market.

Driven by a shared mission, both companies are excited to launch the CATUG-Crystal Joint Lab, aiming to serve as a solution provider to tackle diverse analytical challenges in the field of mRNA and nucleic acid therapeutics. The combined objective is to deliver advanced characterization capabilities and a full range of analytical services to support various stages of drug development for nucleic acid-based therapeutics. With joint lab locations in New Jersey and Boston, this collaborative effort delivers on the commitment to provide services to ensure local accessibility, quality, speed, and flexibility.

"Given the rapid evolution of mRNA and nucleic acid therapeutics, there is a growing demand for adept analytical solutions. CATUG has been steadfast in its mission to pioneer top-notch platforms supporting comprehensive solutions in nucleic acid-based therapeutics. Its analytical platforms have been meticulously developed, boasting over 80 platform methods tailored for release & stability testing and extended characterization of DNA, RNAs, and diverse nanoparticle formulations. We are honored to form this partnership with CATUG. Together, we will provide top-notch analytical services to support nucleic acid discovery and development in North American pharmaceutical hubs", said Dr. Alex Chen, co-founder and CEO of Crystal Pharmatech.

Dr. Lin Jin, co-founder and CTO of CATUG, also expressed her excitement for this partnership saying, "Crystal Bio is the premier CRO for intricate analytical challenges in CMC, preclinical, and clinical samples for a range of biologic products, including proteins, peptides, antibodies, ADCs, nucleic acids, and more. We are truly thrilled about our partnership with Crystal Bio. This partnership underscores both parties' shared vision for innovation, quality, and excellence. The launch of CATUG-Crystal joint lab exemplifies our commitment to delivering advanced services that are crucial for various stages of drug development. Together, we are poised to set new standards in the industry, offering cutting-edge analytical solutions tailored to the evolving needs of our clients."

CATUG and Crystal Bio are confident that by combining the local analytical prowess of Crystal Bio with CATUG's proficient expertise in integrated nucleic acids analytical platforms, CATUG-Crystal will deliver best-in-class analytical services and drive advancements in nucleic acid-based drug development to the North American market.

About CATUG

CATUG is a specialized Contract Research, Development, and Manufacturing Organization (CRDMO) and a one-stop solution in nucleic acid-based therapeutics through its leading DNA, RNA, LNP, and analytical platforms. With strong expertise and know-how, CATUG aims to provide customized solutions in the life cycle of mRNA therapeutics, gene editing, and gene and cell therapy development. For more detailed information on CATUG, please visit https://catug.bio/

About Crystal Bio

Built from Crystal Pharmatech, the leader in crystal form and formulation services, Crystal Bio is a dedicated biologics analytical CRO in the USA. Crystal Bio is committed to addressing the intricate and analytical challenges in CMC, pre-clinical, and clinical samples for biologic products with speed and complete flexibility. For more detailed information on Crystal Bio, please visit https://www.crystalpharmatech.com/crystal-bio/.

For more information, please visit here or contact us via [email protected]


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.